Evidence map›Paper›PMID 38285081›Full record

ReviewAnnals of hematology2024

Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.

Qiuyan Wang, Yajing Zhao, Xiao Zang, Guizhi Zhou, Yongxia Liu, Qi Feng, Xin Li, Wen Wang, Xiaoyuan Dong, Xinguang Liu and 2 more

Abstract readReviewCase Reports
PubMed Publisher
In one paragraph

Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Qiuyan Wang *Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China.
Yajing Zhao *Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Xiao ZangShandong Provincial Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
Guizhi ZhouShandong Provincial Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
Yongxia LiuShandong Provincial Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong, China.
Qi FengDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Xin LiDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Wen WangDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Xiaoyuan DongDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Xinguang LiuDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China. liuxingrant@163.com.
Jun PengDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China.
Chuanfang LiuDepartment of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, 250012, Shandong, China. lcfsy@163.com.
Qilu Hospital of Shandong University · CNShandong University · CNShandong Provincial Institute of Dermatology and Venereology · CNShandong First Medical University · CN

Funding

National Natural Science Foundation of China 82170123
6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is highly aggressive with a poor prognosis. There is no standard treatment for BPDCN. Although conventional chemotherapies are usually sensitive in the initial therapy, relapse and drug resistance are inevitable within a short duration. Targeted therapies have enlightened new prospects for the treatment of BPDCN, especially for those in a frail state and intolerable to standard chemotherapies or hematopoietic stem cell transplantation. Here, we report an 82-year-old man diagnosed with cutaneous-limited BPDCN. Considering the old age and limited involvement of the tumor, we reduced the dosage of venetoclax. His skin lesions subsided significantly after 1 cycle of azacytidine (100 mg d1-7) combined with reduced doses of venetoclax (200 mg d1-14). The reduction in the dose of venetoclax avoided severe myelosuppression while achieving satisfactory outcomes. The patient received 2 cycles of therapy with no skin lesions re-occurred for 7 months before relapsing.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicHematologic NeoplasmsMyeloproliferative DisordersSkin NeoplasmsSulfonamidesAged, 80 and overAzacitidineDendritic CellsHumansMaleNeoplasm Recurrence, LocalAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxAzacitidineBlastic plasmacytoid dendritic cell neoplasmVenetoclax

Identifiers

PMID38285081
OpenAlexW4391311635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.